Guggenheim maintains Buy rating on ArriVent BioPharma, $30 price target

Guggenheim kept a Buy rating on ArriVent BioPharma (AVBP) with a $30 price target, suggesting a 95.3% upside from the Oct 26 close. The firm cited promising early Phase 1 data for ARR-217 in metastatic colorectal cancer, raising its probability of success to 45%. Recent analyst price targets for AVBP range from $18 to $29.

Original reporting
Published Oct 27, 2026, 1:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 1:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Guggenheim maintains Buy rating on ArriVent BioPharma, $30 price target — source image
Decision brief

The 30-second read

$AVBPBullishMed
01

Why it matters

The analyst upgrade and $30 price target provide a fresh catalyst that could attract new buying interest, especially given the sizable upside implied.

02

Market read

The rating change is a primary, material event for AVBP, offering a clear short‑term trade idea for investors seeking upside in biotech.

03

What to watch

Potential competition from other CDH17‑targeted ADCs and the need for larger trials could delay or diminish value.

Relevance 7/10Novelty 7/10Timing: post-market today

Background

ArriVent BioPharma (AVBP) is a clinical‑stage biotech developing antibody‑drug conjugates. The firm recently reported early Phase 1 data for its lead candidate ARR‑217 in metastatic colorectal cancer.

Company-level read

Ticker impact

$AVBPBullishHigh confidence
Context

Guggenheim upgraded ArriVent BioPharma to Buy and raised its price target to $30, implying a 95% upside from the recent close.

Expected impact

likely upward pressure as investors price in the new target

Evidence & confidence

The rating change is a fresh, primary disclosure with a concrete price target, providing a clear catalyst for short‑term buying.

Market effects

Positive sentiment may spill over to other biotech firms with early‑stage ADC pipelines.

Limited to US biotech sector; no broader regional effect.

Minor global impact; primarily relevant to US‑listed biotech investors.

Counterpoint

The early Phase 1 data are still limited; the 38% ORR may not translate to later‑stage success, so the target could be overly optimistic.

Key entities

  • Guggenheim

    Equity research firm that issued the Buy rating and new price target.

  • ArriVent BioPharma

    Biotech developing ADCs, subject of the rating upgrade.

Related articles

$AVBPHighAI 8/10

ArriVent Reports Q3 2026 Results; FURVENT Misses Primary Endpoint, ALPACCA Enrollment Continues

ArriVent BioPharma (AVBP) reported Q3 2026 results, with R&D expenses at $38.9M and net loss widening to $40.3M. The FURVENT trial missed its primary endpoint, but ALPACCA enrollment continues. ARR-217 showed promising preliminary data, and ARR-002's first-in-human study began. Cash reserves are $393.2M, expected to last until mid-2028. AVBP stock closed at $14.16, up 3.81%.

$AVBPMed

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2026 Financial Results · Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC · Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO · Dosed

$AVBPMedAI 8/10

Truist raises ArriVent BioPharma stock price target on drug data

Truist raised its price target for ArriVent BioPharma (AVBP) to $21, citing positive early data for ARR-217 in treating metastatic colorectal cancer. The drug showed a 44.8% preliminary response rate and favorable tolerability. Truist expects Phase 1b data in early 2027. AVBP's stock is down 27% from last week, trading at $15.26. Other analysts have mixed views following a Phase 3 trial failure for firmonertinib.

$AVBPMedAI 9/10

ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

ArriVent BioPharma (NASDAQ:AVBP) reported ARR-217 showed a 44.8% response rate in colorectal cancer study. Key data: 50% in RAS-mutant, 42% in RAS wild-type, 43.5% in irinotecan-treated patients. Phase Ib study ongoing; Phase III trial planned by 2027 end. Common adverse events included anemia, neutropenia, and diarrhea. Company also advancing ARR-002 and firmonertinib in NSCLC.

$AVBPHighAI 9/10

ArriVent BioPharma Reports 44.8% Response Rate for ARR-217 in Phase 1 CRC Data

ArriVent BioPharma reported Phase 1 data for ARR-217, showing a 44.8% response rate at 6 mg/kg in pretreated colorectal cancer patients. The disease control rate was 93.1% at this dose. At 4 mg/kg and higher, the response rate was 34.2% with a 91.8% disease control rate. Grade 3 or higher adverse events occurred in 30.1% of patients. The company plans to advance to Phase 1b dose optimization.